Siemens AG  is a leading technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In fiscal 2023, which ended on September 30, 2023, the Siemens Group generated revenue of €77.8 billion and net income of €8.5 billion. As of September 30, 2023, the company employed around 320,000 people worldwide. 

They joined EU Biotech Campus in April 2024.

The Biotech Campus has announced its partnership with Siemens, a leader in industry, infrastructure, transport, and healthcare. This partnership is crucial for the EUBC, as explained by its President Frédéric Druck: “Such a collaboration paves the way for real progress in the sector, particularly in terms of the digital twin concept, which was already mentioned in the EUBC’s initial strategic plan.” Indeed, a Digital Twin Academy will be established in the new building, with Siemens providing the first training on this future-proof skill by the end of the first half of this year. 

Siemens is delighted to join forces with EU Biotech campus to set up the Digital Twin Academy,” says Thierry Van Eeckhout, Senior Vice-President and Head Siemens Digital Industries Belgium.  “Digital Twin technology is one of the cornerstones of the Siemens portfolio and plays a crucial role within the industry to meet the challenges of today and tomorrow. The further digitalization of the Belgian and European biotech sector remains of great importance, and only has a chance to succeed if it is driven by collaboration in a broad ecosystem of promising companies, sustainable visions and sufficient talent in the field. We are therefore happy to share our expertise and hope in this way to strengthen the growth of and innovation in the biotech sector.”


Stäubli, with a history of innovation such as Stericlean robots designed for aseptic environments, has been a longstanding partner in pharmaceutical automation and is continuously expanding its robotics portfolio.

Biotech automation, particularly robot-based solutions, is becoming increasingly important due to its flexibility, reliability, and ability to minimize human contact, thus reducing contamination risks.

Drawing on extensive collaboration and experience, Stäubli supports customers in a wide range of pharmaceutical and biotech production processes, positioning itself as a dependable specialist in robotics and automation.

They joined EU Biotech Campus in April 2024 

Staubli Robotics is proud to introduce its robotics knowledge and expertise in biotechnology at EU Biotech Campus, said Benjamin Parent, Area Sales Manager.

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan. The manufacturing site of Takeda in Lessines counts 1,200 employees, from 23 nationalities, which are dedicated to delivering products on time and with the highest level of quality to – currently – over 250,000 patients in 80 countries worldwide per year. The site’s purpose is to serve patients with rare diseases and other special conditions. It is a Centre of Excellence for the purification of immunoglobulins, with filling and packaging capacity for plasma-derived therapies and packaging capacity for hematology products.

They joined EU Biotech Campus in April 2024 

“Investing in upskilling and reskilling is crucial in the rapidly changing world of life sciences. That’s why at Takeda, we prioritize talent development as the future of healthcare depends on nurturing the brightest minds. We want to make sure that our workforce evolves in harmony with the latest technologies, using AI, Augmented Reality and Virtual Reality to drive progress and innovation in the long run. Our ambition is not only to shape the future of medicine but also the future of talent, said Geoffrey Pot, General Manager Operations at Takeda. 

They joined EU Biotech Campus in February 2024